Telomir Pharms Financials
Financial Health Signals
Telomir Pharms passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Telomir Pharms generates $0.31 in operating cash flow (-$5.1M OCF vs -$16.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Telomir Pharms (TELO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Telomir Pharms reported -$16.5M in net income in fiscal year 2024. This represents a decrease of 26.5% from the prior year.
Telomir Pharms earned $0.56 per diluted share (EPS) in fiscal year 2024. This represents an increase of 16.7% from the prior year.
Telomir Pharms held $1.3M in cash against $0 in long-term debt as of fiscal year 2024.
Telomir Pharms had 30M shares outstanding in fiscal year 2024. This represents an increase of 4.0% from the prior year.
Telomir Pharms invested $2.2M in research and development in fiscal year 2024. This represents an increase of 42.0% from the prior year.
TELO Income Statement
| Metric | Q3'25 | Q3'24 | Q1'23 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $760K+21.1% | $627K+42.5% | $440K+67.7% | $263K-60.7% | $668K | N/A |
| SG&A Expenses | $387K-92.8% | $5.4M+12525.3% | $43K-58.3% | $102K+70.0% | $60K | N/A |
| Operating Income | $2.2M+14.2% | $1.9M | N/A | N/A | N/A | N/A |
| Interest Expense | $1K-100.0% | $4.3M | N/A | $757K+510.4% | $124K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.1M+81.6% | -$6.0M+35.8% | -$9.3M-445.0% | -$1.7M-10.4% | -$1.6M | N/A |
| EPS (Diluted) | $-0.03+85.0% | $-0.20-900.0% | $-0.02+66.7% | $-0.060.0% | $-0.06 | N/A |
TELO Balance Sheet
| Metric | Q3'25 | Q3'24 | Q1'23 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|
| Total Assets | $7.4M+459.1% | $1.3M-72.3% | $4.8M | N/A | N/A | $49K |
| Current Assets | $7.4M+459.1% | $1.3M+204.2% | $435K | N/A | N/A | $49K |
| Cash & Equivalents | $7.3M+478.9% | $1.3M+102753.9% | $1K | N/A | N/A | $1K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $423K-37.9% | $681K-49.0% | $1.3M | N/A | N/A | $986K |
| Current Liabilities | $423K-37.9% | $681K-49.0% | $1.3M | N/A | N/A | $986K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.0M+985.4% | $643K-81.3% | $3.4M+57.9% | $2.2M-44.0% | $3.9M+515.0% | -$937K |
| Retained Earnings | -$38.9M-27.3% | -$30.6M-117.6% | -$14.1M | N/A | N/A | -$992K |
TELO Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q1'23 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$927K-53.1% | -$606K+44.3% | -$1.1M+45.7% | -$2.0M-5866.2% | -$34K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $7.5M+623.2% | $1.0M-4.5% | $1.1M-45.5% | $2.0M+4191.2% | $46K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
TELO Financial Ratios
| Metric | Q3'25 | Q3'24 | Q1'23 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -14.9%+560.0pp | -574.9%-379.5pp | -195.4% | N/A | N/A | N/A |
| Current Ratio | 17.51+15.6 | 1.94+1.6 | 0.33 | N/A | N/A | 0.05 |
| Debt-to-Equity | 0.06-1.0 | 1.06+0.7 | 0.39 | N/A | N/A | -1.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Telomir Pharms profitable?
No, Telomir Pharms (TELO) reported a net income of -$16.5M in fiscal year 2024.
What is Telomir Pharms's earnings per share (EPS)?
Telomir Pharms (TELO) reported diluted earnings per share of $0.56 for fiscal year 2024. This represents a 16.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Telomir Pharms's operating cash flow?
Telomir Pharms (TELO) generated -$5.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Telomir Pharms's total assets?
Telomir Pharms (TELO) had $1.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Telomir Pharms spend on research and development?
Telomir Pharms (TELO) invested $2.2M in research and development during fiscal year 2024.
How many shares does Telomir Pharms have outstanding?
Telomir Pharms (TELO) had 30M shares outstanding as of fiscal year 2024.
What is Telomir Pharms's current ratio?
Telomir Pharms (TELO) had a current ratio of 1.94 as of fiscal year 2024, which is generally considered healthy.
What is Telomir Pharms's debt-to-equity ratio?
Telomir Pharms (TELO) had a debt-to-equity ratio of 1.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telomir Pharms's return on assets (ROA)?
Telomir Pharms (TELO) had a return on assets of -1248.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Telomir Pharms's cash runway?
Based on fiscal year 2024 data, Telomir Pharms (TELO) had $1.3M in cash against an annual operating cash burn of $5.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Telomir Pharms's Piotroski F-Score?
Telomir Pharms (TELO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telomir Pharms's earnings high quality?
Telomir Pharms (TELO) has an earnings quality ratio of 0.31x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.